LNTH Stock — Lantheus Holdings Inc.: Cash, EV, Pipeline

What they do

We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.

Source: 10-K FY2025 via SEC EDGAR

Share price

$101.49

Market cap

$6,637.5M

Cash

$683.6M

Enterprise value

$5,954.5M

Balance sheet

Cash	$683.6M
Debt	$0.6M
Net cash	$683.0M
Enterprise value	$5,954.5M
Basic shares	65.4M shares
Fully diluted shares	79.3M shares
Fully diluted market cap	$8,045.8M
Cash per share	$10.45
Quarterly burn	+$92.2M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

65.3M

Pre-funded warrants

0.0M

Options

4.2M

RSUs

2.1M

Warrants

0.0M

Converts

7.2M

Conv preferred

0.0M

ESPP reserve

0.5M

FDSO

79.3M

Cap table as of 2026-11-02.

Price history

Loading LNTH daily closes…

Loading price history…

Next catalyst

Florbetaben F18 · Now - Nov 24, 2026 Now · Phase 1 · Cardiac Amyloidosis

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	Florbetaben F18	Phase 1	Cardiac Amyloidosis	—
Jul 13 - Aug 24 in 8 mo	[18F]PI-2620	Phase 3	Alzheimer Disease	—
Sep 12 - Oct 24 in 10 mo	LNTH2403 Phase 1 dose	Phase 2	Relapsed / Refractory Osteosarcoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PYLARIFY

Approved · Active Modality: F-18-labeled PET imaging agent

Aliases piflufolastat F-18, 18F-DCFPyL, PyL

Target PSMA

Indications

PET imaging of PSMA-positive lesions in prostate cancer (initial staging and recurrent disease) (Approved)

Status note F-18 PET imaging agent targeting PSMA; FDA approved May 2021, commercially launched in US Jun 2021.

DEFINITY

Approved · Active Modality: injectable ultrasound enhancing agent (perflutren lipid microspheres/microbubbles)

Indications

Echocardiography (suboptimal echo): opacify left ventricular chamber and improve endocardial border delineation (Approved)

Status note Injectable ultrasound enhancing agent approved for adult and pediatric patients. In Jun 2026 the company repurchased the DEFINITY license in China from its distributor.

Neuraceq

Approved · Active Modality: F-18-labeled PET imaging agent

Target beta-amyloid

Partnerships Clinical development partnerships using Neuraceq as a research tool (see status note)

Indications

PET imaging of brain to estimate amyloid beta neuritic plaque density (Alzheimer's diagnostic) (Approved)

Status note Binds beta-amyloid plaques; FDA approved 2014. Acquired via LMI (Life Molecular Imaging) acquisition (Jul 2025; earn-out/milestones on Neuraceq and other pipeline assets). Filing notes development partnerships using Neuraceq, MK-6240 or NAV-4694 as research tools.

NAV-4694

Phase 3 · Active Modality: F-18-labeled PET imaging agent

Target beta-amyloid

Partnerships Acquired via Meilleur acquisition (Jun 18, 2024)

Indications

Alzheimer's disease (beta-amyloid PET imaging) (Phase 3)

Status note Investigational late-stage F-18-labeled PET imaging agent targeting beta amyloids in Alzheimer's disease; filing notes further development/commercialization plans alongside MK-6240.

LNTH-1363S

Phase 1 · Active Modality: copper-64-labeled PET imaging agent

Target FAP alpha

Partnerships Ratio Therapeutics LLC (previously Noria Therapeutics, Inc.): collaboration

Indications

Oncology and fibrosis (PET imaging) (Phase 1)

Status note Fibroblast activation protein-alpha-targeting diagnostic candidate; Phase 1 study completed to evaluate imaging applicability.

RM2

Stage not disclosed · Active Modality: radiotherapeutic (177Lu-DOTA-RM2) and radiodiagnostic (68Ga-DOTA-RM2) pair

Target GRPR

Partnerships Global rights acquired Jul 3, 2024; royalties on net sales

Indications

Oncology (radiotherapeutic/radiodiagnostic pair) (Stage not disclosed)

Status note Gastrin-releasing peptide receptor-targeting agent; clinical-stage radiotherapeutic and radiodiagnostic pair.

PNT2003

Stage not disclosed · Active

Target PSMA

Partnerships POINT Biopharma Global Inc. (acquired by Lilly Dec 2023): exclusive worldwide rights (excl. Japan, South Korea, China, Singapore) licensed to Lantheus Dec 2022; POINT curates data for regulatory approval, Lantheus seeks approvals

Indications

Oncology (PSMA-targeted) (Stage not disclosed)

Status note Strategic collaboration for PNT2003; Lantheus responsible for preparing for and seeking regulatory approval.

LNTH-2501

Phase 3 · Active

Target Somatostatin receptor

Indications

Not disclosed (Phase 3)

Status note NDA under FDA review; PDUFA target action date extended Mar 17, 2026 (Mar 29 to Jun 29, 2026); FDA issued a Complete Response Letter on Jun 26, 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	[18F]PI-2620
Lead indication	Alzheimer Disease
Lead phase	Phase 3
Active trials	6
Collaborator trials	12

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05641688	Phase 3	Recruiting	Sponsor	LNTH	—	Alzheimer Disease	—
NCT07357519	Phase 2	Recruiting	Sponsor	LNTH	—	Relapsed / Refractory Osteosarcoma	—
NCT06298916	Phase 2	Recruiting	Sponsor	LNTH	—	Metastatic Sarcoma; Esophageal Cancer; Gastric Cancer	—
NCT06790394	Phase 1	Recruiting	Sponsor	LNTH	—	Cardiac Amyloidosis	—
NCT05712473	Not disclosed	Active, not recruiting	Sponsor	LNTH	—	Prostate Cancer	—
NCT06074510	Not disclosed	Active, not recruiting	Sponsor	LNTH	—	Prostate Cancer	—
NCT04557501	Phase 3	Active, not recruiting	Collaborator	Centre hospitalier de l'Université de Montréal (CHUM)	—	Prostate Cancer	—
NCT03976843	Phase 2	Active, not recruiting	Collaborator	National Cancer Institute (NCI)	—	Prostate Cancer	—
NCT07364071	Phase 2	Recruiting	Collaborator	University of California, San Diego	—	Prostate Adenocarcinoma	—
NCT07645326	Phase 2	Not yet recruiting	Collaborator	Georgetown University	—	Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	—
NCT05394259	Phase 1	Active, not recruiting	Collaborator	M.D. Anderson Cancer Center	—	Pancreatic Cancer; Breast Cancer; Hepatocellular Carcinoma	—
NCT07501650	Phase 1	Recruiting	Collaborator	Thomas Jefferson University	—	Head and Neck Cancer; Head and Neck Small Cell Carcinoma; Metastatic Head and Neck Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 12 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 18 active trials for Lantheus Biosciences Ltd. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Deerfield Management	752,999	-75,000	0.87%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

LNTH — Lantheus Holdings Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

LNTH — Lantheus Holdings Inc.